Abstract
Small molecules such as retinoids, steroid hormones, fatty acids, cholesterol metabolites, or xenobiotics are involved in the regulation of numerous physiological and patho-physiological processes by binding to and controlling the activity of members of the nuclear receptor (NR) superfamily of transcription factors. In addition to natural ligands, synthetic agonists or antagonists have been identified that in some cases specifically target NR isotypes, or elicit tissue- , signaling pathway-, or promoter-selective transcriptional responses. For these ligands the term ‘selective NR modulators’ (SNRMs) has been introduced. Structure determination of apo- and holo-NR ligand-binding domains (LBDs) - some of them complexed to small coactivator or corepressor fragments - revealed the major principles of ligand-dependent NR action and determinants of (isotype-) selective ligand binding. These studies also stimulated the interpretation of tissuespecific effects of SNRMs on wild-type or mutant receptors. In contrast to the increasing knowledge on the structureactivity relationship of NRs with known SNRMs, rather basic questions remain about the regulation of orphan NRs (for which no ligands are known) or ‘adopted’ orphan NRs (for which only recently ligands were identified). Several crystal structures of orphan NR LBDs uncovered unexpected properties, contributed to the understanding of orphan NR function, and may in the future permit the identification or design of ligands. This review will (i) focus on the current understanding of the structure-activity relationship of NR-ligand interactions, (ii) discuss recent advances in the field of ‘orphan’ NR crystallography, and (iii) outline future challenges in NR structural biology.
Keywords: structure-activity relationship, snrms, holo-NR ligand-binding domains, selective nr modulators, promoter-selective transcriptional responses, transcription factors, nuclear receptor (nr) superfamily, nuclear receptor-ligand interactions
Current Topics in Medicinal Chemistry
Title: Structure-Activity Relationship of Nuclear Receptor-Ligand Interactions
Volume: 3 Issue: 14
Author(s): Holger Greschik and Dino Moras
Affiliation:
Keywords: structure-activity relationship, snrms, holo-NR ligand-binding domains, selective nr modulators, promoter-selective transcriptional responses, transcription factors, nuclear receptor (nr) superfamily, nuclear receptor-ligand interactions
Abstract: Small molecules such as retinoids, steroid hormones, fatty acids, cholesterol metabolites, or xenobiotics are involved in the regulation of numerous physiological and patho-physiological processes by binding to and controlling the activity of members of the nuclear receptor (NR) superfamily of transcription factors. In addition to natural ligands, synthetic agonists or antagonists have been identified that in some cases specifically target NR isotypes, or elicit tissue- , signaling pathway-, or promoter-selective transcriptional responses. For these ligands the term ‘selective NR modulators’ (SNRMs) has been introduced. Structure determination of apo- and holo-NR ligand-binding domains (LBDs) - some of them complexed to small coactivator or corepressor fragments - revealed the major principles of ligand-dependent NR action and determinants of (isotype-) selective ligand binding. These studies also stimulated the interpretation of tissuespecific effects of SNRMs on wild-type or mutant receptors. In contrast to the increasing knowledge on the structureactivity relationship of NRs with known SNRMs, rather basic questions remain about the regulation of orphan NRs (for which no ligands are known) or ‘adopted’ orphan NRs (for which only recently ligands were identified). Several crystal structures of orphan NR LBDs uncovered unexpected properties, contributed to the understanding of orphan NR function, and may in the future permit the identification or design of ligands. This review will (i) focus on the current understanding of the structure-activity relationship of NR-ligand interactions, (ii) discuss recent advances in the field of ‘orphan’ NR crystallography, and (iii) outline future challenges in NR structural biology.
Export Options
About this article
Cite this article as:
Greschik Holger and Moras Dino, Structure-Activity Relationship of Nuclear Receptor-Ligand Interactions, Current Topics in Medicinal Chemistry 2003; 3 (14) . https://dx.doi.org/10.2174/1568026033451736
DOI https://dx.doi.org/10.2174/1568026033451736 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Up-Regulation of Gr1+CD11b+ Population in Spleen of Dextran Sulfate Sodium Administered Mice Works to Repair Colitis
Inflammation & Allergy - Drug Targets (Discontinued) Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Human Immunodeficiency Virus-Associated Malignancies: A Therapeutic Update
Current HIV Research Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Classification of Malignant and Benign Micro Calcifications from Mammogram Using Optimized Cascading Classifier
Current Signal Transduction Therapy Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Topoisomerase 1B as a Target Against Leishmaniasis
Mini-Reviews in Medicinal Chemistry Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine N-Succinyl Chitosan as Buccal Penetration Enhancer for Delivery of Herbal Agents in Treatment of Oral Mucositis
Current Drug Delivery The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets